Main content area

Cardamonin: A new player to fight cancer via multiple cancer signaling pathways

Nawaz, Javaria, Rasul, Azhar, Shah, Muhammad Ajmal, Hussain, Ghulam, Riaz, Ammara, Sarfraz, Iqra, Zafar, Saba, Adnan, Muhammad, Khan, Abdul Haleem, Selamoglu, Zeliha
Life sciences 2020 v.250 pp. 117591
antineoplastic agents, apoptosis, beta catenin, biosafety, carcinogenesis, cell cycle, chalcone, cytokines, cytotoxicity, drug development, enzymes, health services, human health, humans, immune system, inflammation, medicinal properties, neoplasms, pathogens, pharmacokinetics, regulatory proteins, signal transduction, therapeutics, transcription factor NF-kappa B
Nature's pharmacy has undoubtedly served humans as an affordable and safer health-care regime for a long times. Cardamonin, a chalconoid present in several plants has been known for a longtime to have beneficial properties towards human health. In this review, we aimed to highlight the recent advances achieved in discovering the pharmacological properties of cardamonin. Cardamonin is cardamom-derived chalcone, which plays a role in cancer treatment, immune system modulation, inflammation and pathogens killing. Through the modulation of cellular signaling pathways, cardamonin activates cell death signal to induce apoptosis in malignant cells that results in the inhibition of cancer development. Moreover, cardamonin arrests cell cycle by altering the expression of regulatory proteins during malignant cells division. Due to its relatively selective cytotoxic potential against host malignant cells, cardamonin is emerging as a promising novel experimental anticancer agent. The potential of cardamonin to target various signaling molecules, transcriptional factors, cytokines and enzymes, such as mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2 enhances the opportunity to explore it as a new multi-target therapeutic agent. The pharmacokinetic and biosafety profile of cardamonin favor it as a potentially safe biomolecule for pharmaceutical drug development.